Osteopore Limited
Osteopore Limited
Your view on OSX.AX
Overview
What the company does, where it operates, and who runs it.
About Osteopore Limited
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Yujing Lim
- Headquarters
- Level 5, 191 St. Georges Terrace, Perth, WA, AU
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Yujing Lim
- Headquarters
- Level 5, 191 St. Georges Terrace, Perth, WA, AU
Established in Singapore in 2003, Osteopore Limited focuses on engineering, manufacturing, and globally commercializing bioresorbable polymer implants. These advanced devices are utilized in neurosurgical, orthopedic, and maxillofacial operations throughout Singapore, Australia, and other international regions.
The company's core innovation involves employing 3D printing with bioresorbable materials to create custom, micro-structured scaffolds specifically designed to foster bone regeneration.
Its product portfolio includes Osteoplug, a resorbable implant for sealing trephination burr holes during neurosurgery, and Osteomesh, another resorbable implant used in craniofacial surgery to mend various fractures, including orbital floor injuries, and to fill surgical voids.
Additionally, Osteopore has forged a collaborative partnership with Livingstone Health Holding Limited to jointly pioneer new products and applications for bone and tissue regeneration.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Osteopore Limited, and the rating behind it. OSX.AX last traded at AUD 0.0050; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Osteopore Limited. Starting points for Osteopore Limited: EPS -AUD 0.0078, beta -0.02 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Osteopore Limited. Osteopore Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Osteopore Limited. Trailing twelve-month EPS for Osteopore Limited stands at -AUD 0.0078. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Osteopore Limited. Osteopore Limited has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Osteopore Limited valued side by side against its closest peers. Osteopore Limited is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Osteopore Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Osteopore Limited executives and directors. Shares of Osteopore Limited have traded between AUD 0.0040 and AUD 0.03 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Osteopore Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Osteopore Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Osteopore Limited. Coverage tracks Osteopore Limited within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.